• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Fluoxetine or Venlafaxine for Early Post Stroke Depression
Conclusions: PSD in the early phase affects a substantial number of the stroke patients. Venlafaxine has got a better outcome and adverse event profile compared to fluoxetine in this group of patients. However, larger multicenter studies will provide more helpful data in this area.
Source: Neurology India - December 19, 2022 Category: Neurology Authors: Vivek K Nambiar J Parvathy Tania M Philip K Abhijith S Sreeni Naveen K Panicker Amrutha V Ajai TS Dhanya Source Type: research

Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania
Post-stroke fluoxetine trials are primarily conducted in high-income countries. We characterize post-ischemic stroke depression in fluoxetine-treated and -untreated study participants in urban Tanzania.
Source: Journal of Stroke and Cerebrovascular Diseases - November 2, 2021 Category: Neurology Authors: Dylan R. Rice, Kigocha Okeng'o, Emmanuel Massawe, Seif Ismail, Notburga A. Mworia, Faraja Chiwanga, Boniface Kapina, Michael Wasserman, Farrah J. Mateen Source Type: research

The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis
Conclusions: Fluoxetine and citalopram can promote motor recovery in non-depressed patients with acute stroke, but it is necessary to pay attention to the possible AEs of fluoxetine, such as hyponatremia, seizure and fracture.Systematic Review Registration: PROSPERO, identifier [CRD42021227452].
Source: Frontiers in Neurology - October 20, 2021 Category: Neurology Source Type: research

Final Word on SSRI for Post-Stroke Depression? Final Word on SSRI for Post-Stroke Depression?
The antidepressant fluoxetine does not prevent or alleviate post-stroke depression, new findings from a randomized, placebo-controlled trial confirm.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - August 12, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Poststroke Selective Serotonin Reuptake Inhibitors
In the community, major risk factors for depression include sex, advancing age, lower income, employment status, and illnesses such as stroke that result in disability and affect income, employment, and social status. Poststroke depression affects 1 in every 3 patients in the first year after stroke occurrence and thereafter. Important general treatments for depression include the selective serotonin reuptake inhibitors; these compounds have also been suggested to modulate motor and functional recovery after stroke. The FLAME (Fluoxetine for Motor Recovery After Acute Ischaemic Stroke) trial kindled interest in treatment w...
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery
This randomized clinical trial investigates whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by symptoms of depression after stroke.
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic
Conclusion: Among patients with stroke, early initiation of fluoxetine did not result in improved functional recovery. Lower rates of depression were observed in the fluoxetine-treated group; however these patients experienced higher rates of bone fracture.
Source: The Neurologist - May 1, 2021 Category: Neurology Tags: Critically Appraised Topics Source Type: research

Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials
Conclusion: In post-stroke treatment, fluoxetine did not improve participants' mRS and NIHSS but improved FMMS and BI. This difference could result from heterogeneities between the trials: different treatment duration, clinical scales sensitivity, patient age, delay of inclusion, and severity of the deficit.
Source: Frontiers in Neurology - March 22, 2021 Category: Neurology Source Type: research

Antidepressant-like effects of paeoniflorin on post-stroke depression in a rat model.
CONCLUSIONS: Observed results suggested that paeoniflorin could ameliorate the symptoms and improve the functional capability of PSD rats, similar to the effect of fluoxetine. ABBREVIATIONS: PSD: post-stroke depression; CUMS: chronic unpredictable mild stress stimulation; MCAO: middle cerebral artery occlusion; OFT: open field test; SPT: sucrose preference test, NDS: neurological deficit score, BBT: beam balance test; BDNF: brain-derived neurotrophic factor protein; p-CREB: phosphorylated Cyclic-AMP responsive element binding protein. PMID: 30759063 [PubMed - as supplied by publisher]
Source: Neurological Research - February 15, 2019 Category: Neurology Tags: Neurol Res Source Type: research

Chronic Fluoxetine Induces Activity Changes in Recovery From Poststroke Anxiety, Depression, and Cognitive Impairment
AbstractPoststroke depression (PSD) is a common outcome of stroke that limits recovery and is only partially responsive to chronic antidepressant treatment. In order to elucidate changes in the cortical-limbic circuitry associated with PSD and its treatment, we examined a novel mouse model of persistent PSD. Focal endothelin-1-induced ischemia of the left medial prefrontal cortex (mPFC) in male C57BL6 mice resulted in a chronic anxiety and depression phenotype. Here, we show severe cognitive impairment in spatial learning and memory in the stroke mice. The behavioral and cognitive phenotypes were reversed by chronic (4-wee...
Source: Neurotherapeutics - December 4, 2017 Category: Neurology Source Type: research

Neuroplasticity and behavioral effects of  fluoxetine after experimental stroke.
Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. Restor Neurol Neurosci. 2017 Aug 24;: Authors: Sun Y, Sun X, Qu H, Zhao S, Xiao T, Zhao C Abstract The brain can undergo self-repair and has the ability to compensate for functions lost after a stroke. The plasticity of the ischemic brain is influenced by several factors including aging and pharmacotherapy. Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin. In clinical practice, fluoxetine alleviates the symptoms of post-stroke depre...
Source: Restorative Neurology and Neuroscience - September 1, 2017 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation
This article evaluates whether specific drugs are able to facilitate motor recovery after stroke or improve the level of consciousness, cognitive, or behavioral symptoms after traumatic brain injury. Recent findings: After stroke, serotonin reuptake inhibitors can enhance restitution of motor functions in depressed as well as in nondepressed patients. Erythropoietin and progesterone administered within hours after moderate to severe traumatic brain injury failed to improve the outcome. A single dose of zolpidem can transiently improve the level of consciousness in patients with vegetative state or minimally conscious stat...
Source: Current Opinion in Neurology - November 8, 2016 Category: Neurology Tags: TRAUMA AND REHABILITATION: Edited by Bruce H. Dobkin Source Type: research

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
ConclusionIn addition to the need of comprehensive‐clinical evidence, further elucidation of the beneficial mechanisms whereby SSRIs may improve structural and functional recovery from ischemic‐brain damage is needed to form a basis for translation into clinical practice. Several clinical studies have indicated that selective serotonin reuptake Inhibitors (SSRIs) administered after acute ischemic stroke can improve clinical recovery independently of depression. However, data from confirmatory trials in large study populations are lacking and the underlying mechanisms are incompletely understood. This review summarizes...
Source: Brain and Behavior - September 1, 2015 Category: Neurology Authors: Timo Siepmann, Ana Isabel Penzlin, Jessica Kepplinger, Ben Min‐Woo Illigens, Kerstin Weidner, Heinz Reichmann, Kristian Barlinn Tags: Review Source Type: research